Rocket Lab (RKLB) Stock Falls 4% as CFO Share Sale and SpaceX Risks Weigh
Key Takeaways
- •Rocket shares closed 4% lower at $65.71 on Monday on volume about 38% below the daily average, extending a 13% loss over the past week.
- •A Japanese satellite company has reportedly contracted 20 additional dedicated Electron launches, adding to a record backlog of $2.36 billion as of June 30.
- •CFO Adam Spice sold 140,157 shares for $9.93 million on October 1 under a Rule 10b5-1 plan, and insiders have sold a combined $26.96 million of stock over the past 90 days.
- •Rocket Lab's latest quarterly results showed a wider-than-expected loss of $0.08 per share, though revenue of $234.07 million beat the $231.62 million estimate.
- •Wall Street coverage remains largely bullish with an average price target of $104.71, although TD Cowen cut its target from $120 to $90 while keeping a Buy rating.

Shares of Rocket Lab USA, Inc. (RKLB) fell 4% on Monday, closing at $65.71 after finishing the prior session at $68.21. The stock traded as low as $65.12 during the session, and volume reached approximately 14.35 million shares, about 38% below the daily average of 22.99 million, meaning the decline came on lighter-than-usual trading. Pre-market trading on Tuesday showed the stock at $64.93, down roughly 1%. Over the past week, the shares have lost 13% of their value.
The move lower came despite a series of recent developments around the company, including new contract activity and a wave of analyst coverage. The company currently carries a market capitalization of $39.32 billion and a beta of 2.93, a measure indicating the stock has historically tended to swing more sharply than the broader market. The stock sits below both its 50-day moving average of $70.52 and its 200-day moving average of $84.44 — technical levels many traders use to gauge short- and long-term trends — underscoring the recent pullback.
Contract Wins and a Record Backlog
A Japanese satellite company has reportedly signed a contract for 20 additional dedicated Electron launches, adding to a record backlog of $2.36 billion as of June 30. Backlog — contracted work not yet converted into revenue — is a closely watched figure for launch providers, since turning it into actual sales depends on flight cadence and execution. Reports also indicate that NASA is weighing bulk rocket purchases to support a lunar-base effort estimated at $30 billion. That prospect has lifted interest in Rocket Lab's Neutron rocket, a medium-lift vehicle that has not yet flown, making its debut one of the company's most closely watched upcoming milestones.
Risks, however, remain firmly in focus. Analysts point to launch execution, orbital-collision management, and intensifying competition from SpaceX. SpaceX's push into satellite-spectrum services could also weaken the strategic case for Rocket Lab's planned Iridium acquisition, and investors are watching closely to see whether the deal can accelerate the company's revenue growth.
Insider Selling Draws Attention
Insider selling has also been part of the picture. Chief Financial Officer Adam Spice sold 140,157 shares of common stock for $9.93 million on October 1, at weighted-average prices ranging from $69.53 to $72.39. The sales were conducted under a Rule 10b5-1 pre-set trading plan that he adopted on June 3 — a mechanism that lets insiders schedule trades in advance and is commonly used to avoid any suggestion of trading on material nonpublic information. Spice also exercised options at $1.09 each for a total of $152,771 and still directly owns 1,155,967 shares, leaving him with a significant direct stake in the company.
Separately, insider Frank Klein sold 35,558 shares at an average price of $66.61 on August 27. In all, insiders have sold a combined $26.96 million worth of stock over the past 90 days — a figure drawing attention as the share price slips.
Analyst Ratings and Earnings
Rocket Lab last reported quarterly results on August 10, posting a loss of $0.08 per share, wider than the expected loss of $0.06. Revenue came in at $234.07 million, however, topping the $231.62 million estimate.
Wall Street coverage remains broadly constructive: four analysts rate the stock Strong Buy, 15 rate it Buy, five say Hold, and one says Sell, producing an average price target of $104.71 — well above the current share price. Citigroup initiated coverage on October 1 with a Buy rating and a $105 target, while Barclays also began coverage with an Overweight rating. TD Cowen maintained its Buy rating but cut its price target from $120 to $90, and Cantor Fitzgerald holds an Overweight rating with a $122 target. ARK Invest reportedly bought about 1.3 million shares, and institutions own 71.78% of the company.
On the technology front, Rocket Lab announced IMM Apex, a germanium-free solar cell designed for space applications, an addition to its space-systems portfolio alongside its launch business. The company expects Neutron and the planned Iridium acquisition to expand its medium-lift launch and spectrum capabilities by 2027.
Source: CoinCentral